| porphyzomes
(porphyrin lipid nanovesicles) |
Photofrin |
PTT (135 J/cm2 at 100 mW/cm2) PDT (671
nm) |
|
|
A549 |
lung cancer (PDT, PTT) |
(252) |
| NAB NPs aza-boron-dipyrromethene
(aza-BODIPY), dimethylaminophenyl
units |
aza-boron-dipyrromethene |
PDD (20
mW/cm2) PTT (20 mW/cm2) |
30 nm |
|
HeLa cells |
Henrietta’s cancer, (PDT, PTT) |
(253) |
| PDA NPs PDA-C6 NPs (polydopamine NPs) |
Chlorin e6 (Ce6) |
PDT-665 nm, Ce6 at (250 mW/cm2) PTT- input energy
of 28.3 J |
141.3 ± 4.3 142.4 ± 4.1 |
–48.7 ± 1.3–45.45 ± 1.4 |
T24 cells |
bladder cancer (PDT, PTT) |
(49) |
| Pt-ICG@PDA Pt- platinum PDA-polydopamine folate labeled liposomes |
indocyanine green (ICG) |
808 nm |
100 nm |
|
MCF-7 cells |
breast cancer (PDT, PTT) |
(254) |
| ZnPc 1,8,15,22-tera-(3-(6-hydroxyl) hexyloxy) phthalocyanine
zinc(II) |
pthalocyanin zinc II |
650 nm (0.7
W/cm2) |
70 nm |
|
HeLa cells L929 U14 |
Henrietta’s
cancer, (PDT, PTT) |
(255) |
| Bi/MnPcE4 i-bismuth |
phthalocyanine manganese |
808
nm (1.0 W/cm2) |
120 nm |
|
HeLa cells |
Henrietta’s
cancer, (PDT, PTT) |
(256) |
| DPP NPs
DPP+ NPs DPP2+NPs diketopyrrolopyrrole-based
photosensitizer |
DPP |
635 nm (0.3 W/cm2) |
200 |
|
HeLa cells |
Henrietta’s
cancer, breast cancer (PDT,
PTT) |
(257) |
| 240 |
|
MCF-7 cells |
| 260 |
35.5 |
L929 cells |
| DPP-TPA NPs
DPP-diketopyrrolopyrrole TPA -triphenylamine |
DPP-diketopyrrolopyrrole |
660 nm (1.0 W/cm2) |
∼76 nm |
|
HeLa cells in vivo HCT-116 cells |
Henrietta’s cancer,
(PDT, PTT) |
(258) |
| PLL-ICG/DPEG NPs PLL- polylysine
ICG- indocyanine green DPEG-polyethylene
glycol |
ICG-indocyanine green |
808 nm (1.5
W/cm2) |
262 nm |
–12 |
HeLa cells |
Henrietta’s cancer, (PDT, PTT) |
(259) |
| CAM NPs chlorin Ce6, axitinib, dextro-1-methyl tryptophan,
human serum albumin |
chlorin e6 |
|
170 nm |
∼10.5 |
B16F10 melanoma cells |
photodynamic immunotherapy |
(260) |
| phthalocyanines, anti-PD-L1 antibody |
phthalocyanines (ZnPcs) |
λ > 610 nm |
|
|
B16–F10 |
skin cancer (PD-IMT) |
(261) |
| mesoporous-silica-coated β-NaYF4: 20%Yb, 2%Er
upconversion
NPs (UCMSs) |
merocyanine 540 |
980 nm |
100 |
|
CT26 cells |
photodynamic immunotherapy (colon cancer) |
(262) |
| Ce6/MLT@SAB boehmite nanorod Ce6-Chlorin e6MLT-
melittin B-aluminum
hydride |
Ce6-Chlorin e6 |
660 nm (0.1 W/cm2) |
184.2 ± 5.4 |
–17.6 ± 1.5 mV |
4T1 cells |
breast cancer (PD-IMT) |
(263) |
| P 127, (NIR-II) window type-I photosensitizers |
PTS |
NIRII laser 1064 nm |
45.5 ± 16.8 |
–8.45, −14.70, −13.27 |
4T1 |
breast cancer (PDT,
PTT) |
(264) |
| PTSe |
38.3 ± 10.6 |
| PTTe |
91.5 ± 13.2 |
| NLG919/IR780 micelles NLG919- indoleamine
2,3-dioxygenase (IDO)
inhibitor |
IR780 |
808 nm (1.0 mW/cm2) |
43 ± 3.2 |
|
MCF-7 cells |
breast cancer
(PD-IMT) |
(265) |
| verteporfin and doxorubicin(DOX)
conjugated cathepsin B-cleavable
peptide linker of FRRG (Phe-Arg-ArgGly) (VPF-FRRG-DOX) |
verteporfin |
671 nm, 40 mW |
87.12 ± 3.95 nm |
|
CT26 and H9C2 |
colon cancer (PDT-IMT) |
(266) |
| pH-responsive DEX-HAase NPs DEX-dextran, HAaase-hyaluronidase |
Chlorin e6 |
660 nm (5 mW/cm2) |
≈97 nm |
|
4T1 |
breast cancer (PD-IMT) |
(267) |
| PEGylated HMCP NCs HMCP-hollow structured manganese carbonate
(MnCO3) nanocubes |
Chlorin e6 |
660 nm (0.1
W/cm2) |
193.0 ± 27.6 nm |
|
HeLa cells |
Henrietta’s
cancer (PDT–CDT) |
(268) |
| lactate oxidase (LOx)
and catalase (CAT) integrated Fe3O4 nanoparticle/indocyanine
green (ICG) coloaded hybrid nanogels |
indocyanine green
(ICG) |
808 nm (0.25 W) |
72.91 |
–22.90 |
not defined |
PDT–CDT |
(269) |
| cancer cell memebrane coated copper/manganese silicate
nanospheres (mCMSNs) a |
copper silicate existing in the CMSNs acted as efficient photosensitizer |
635 nm (0.6 W/cm2) |
∼25 nm |
∼10 mV |
MCF-7 NHDF |
breast cancer
(PDT–CDT) |
(270) |
| copper/manganese silicate
nanosphere (CMSN)- coated lanthanide-doped
NPs (LDNPs) (LDNPs@CMSNs) |
upon NIR light excitation,
the CMSNs act as photosensitizers |
980 nm (0.5 W/cm2) |
45 nm |
|
HeLa cells |
Henrietta’s
cancer (PDT–CDT) |
(271) |
| tumor microenvironment
(TME)-responsive Fe(III)–porphyrin
(TCPP) coordination NPs (FT@HA NPs) |
Fe(III)–porphyrin |
635 (100 mW/cm2) |
160 ± 33 nm in length 90 ± 12 nm in width |
–14.56 mV |
4T1 cells and NIH-3T3 cells |
breast cancer
(PDT–CDT) |
(272) |
| BSO-FeS2 NPs BSO- L-buthionine-sulfoximine |
|
808 nm |
7.27 ± 1.43 nm |
|
4T1 cell line |
breast
cancer (PDT–CDT) |
(273) |
